BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology cancer therapies. The Companyâ€™s lead product Plinabulin, is being studied in late-stage clinical trials as an anti-cancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). The Company's product, Plinabulin, is a marine-derived small-molecule with a range of biological activities. Plinabulin targets cells in the tumor vasculature resulting in selective anti-tumor activity. Plinabulin has also demonstrated a range of immuno-stimulatory effects, including stimulating the maturation of dendritic cells, increasing cytokine secretion, downregulating inhibitory T-cells, and stimulating tumor-antigen-specific T-cell activation.
Number of employees : 61 people.
|Vote ||Quantity||Free-Float||Company-owned shares||Total Float
|Lan Huang ||10,367,037||
|Decheng Capital LLC ||3,458,142||
|Mulong Liu ||2,105,494||
|Quan Qi Song ||689,759||
|HBM Partners AG (Investment Management) ||285,130||
|Ramon W. Mohanlal ||220,098||
|SSgA Funds Management, Inc. ||216,606||
|Northern Trust Investments, Inc.(Investment Management) ||167,870||
|BlackRock Fund Advisors ||166,707||
|Shanghai Fosun Industry Investment Co., Ltd. ||155,564||
|Company contact information|
Sector Bio Therapeutic Drugs
Connections : BeyondSpring Inc.